DBV Technologies previously announced that it had raised €166.7 million in gross proceeds from the full exercise of warrants ...
Châtillon, France, January 16, 2026DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of ...
AMF Regulated InformationChâtillon, France, January 7, 2026Half-Year Report on the DBV Technologies Liquidity Contract with ...
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a late-stage biopharmaceutical company, today announced that VITESSE, its pivotal Phase 3 study ...
Fintel on MSN
DBV Technologies SA - Depositary Receipt (DBVT) price target decreased by 13.27% to 21.61
The average one-year price target for DBV Technologies S.A. - Depositary Receipt (NasdaqCM:DBVT) has been revised to $21.61 / share. This is a decrease of 13.27% from the prior estimate of $24.92 ...
DBV to pursue an Accelerated Approval pathway for toddlers ages 1 – 3 years-old BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers ...
Two of the leaders responsible for regulatory and product development at DBV Technologies are set to leave the company this month. The departures deprive DBV of senior members of its regulatory team ...
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced positive twenty-four month results from its Open-Label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback